Key facts
- Ambros Therapeutics’s last known valuation is $250.0M (Dec 2025).
- It has raised $154.0M across 1 recorded rounds; the latest was Early Stage VC (Series A) ($154.0M) in Dec 2025.
- Notable investors include RA Capital Management, Arkin Capital, Adage Capital Management, Balyasny Asset Management, Abiogen Pharma — 9 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Ambros Therapeutics
Funding rounds
1 roundsAbout Ambros Therapeutics
Operator of a therapeutics company intended to address Complex Regional Pain Syndrome Type 1 (CRPS-1). The company offers a Phase 3 pivotal trial program of neridronate (a differentiated bisphosphonate) for patients with CRPS-1, enabling clinicians and patients to access a potential treatment where no FDA-approved medicine currently exists for this condition.
- Industry
- Biotechnology
- Sector
- Healthcare
- HQ
- Irvine, CA, United States
- Founded
- 2024
- Employees
- 14
- Website
- ambrostherapeutics.com/
- Ownership
- Privately Held (backing)
Ambros Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ambros Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ambros Therapeutics in its N-PORT filings yet. We sweep new filings monthly.